Loading clinical trials...
Loading clinical trials...
A Phase 1b/2a, Randomized, Double-blind Study to Investigate Safety, Tolerability, PK, PD, and Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplantation Receiving Fluoroquinolone Prophylaxis and Harboring Fluoroquinolone-Resistant Escherichia Coli Pre-Transplant
Conditions
Interventions
SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli
Placebo 10 mL
Locations
8
United States
City of Hope
Duarte, California, United States
University of California, San Francisco
San Francisco, California, United States
John Hopkins University
Baltimore, Maryland, United States
University of Minnesota
Minneapolis, Minnesota, United States
Weill Cornell Medicine
New York, New York, United States
UPMC
Pittsburgh, Pennsylvania, United States
Start Date
February 25, 2025
Primary Completion Date
April 1, 2026
Completion Date
April 1, 2026
Last Updated
October 14, 2025
NCT07280598
NCT00877708
NCT00363220
NCT00619580
Lead Sponsor
SNIPR Biome Aps.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions